Prevalence of Polypharmacy in Elderly Population Worldwide: A Systematic Review and Meta‐Analysis
Prävalenz von Polypharmazie in der älteren Bevölkerung weltweit: systematische Übersicht und Metaanalyse
Pharmacoepidemiology and Drug Safety · 2024-08 · 33 (8)
DOI: 10.1002/pds.5880 ↗Auf einen Blick
Die Metaanalyse zeigt weltweit eine Prävalenz von Polypharmazie von 39,1 % bei älteren Menschen. Hyperpolypharmazie lag bei 13,3 %.
Fragestellung
Wie hoch ist die weltweite Prävalenz von Polypharmazie bei älteren Menschen, und welche Faktoren sind damit verbunden?
Methode
Systematische Übersicht und Metaanalyse von Beobachtungsstudien; Suche in PubMed, Web of Science, Cochrane Library und Ovid EMBASE bis 30. Mai 2022.
Ergebnisse
122 Beobachtungsstudien mit 57 328 043 Personen. Polypharmazie: 39,1 % (95 %-KI 35,5–42,7); Hyperpolypharmazie: 13,3 % (95 %-KI 10,4–16,5).
Schlussfolgerung der Autor:innen
Fast 40 % der älteren Bevölkerung sind Polypharmazie ausgesetzt. Höhere Prävalenzen wurden bei Menschen ab 70 Jahren, in entwickelten Regionen und in Pflegeheimen gefunden.
Kernaussagen
- Polypharmazie weltweit: 39,1 %
- Hyperpolypharmazie: 13,3 %
- Höhere Prävalenz in Europa/Nordamerika, ab 70 Jahren und in Pflegeheimen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 13.08.2024. Verfasst von Zeyu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Ce…. Hauptthemen laut MEDLINE: Polypharmacy. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, National Key Research and Development Program of China.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Background
Polypharmacy (PP) is common in elderly population and associated with some adverse clinical outcomes and increases healthcare burdens. We performed this systemic review and meta‐analysis to estimate worldwide prevalence of PP and explore associated factors in the elderly.
Methods
The PubMed, Web of Science, Cochrane Library, and Ovid EMBASE databases were searched for studies published until May 30, 2022. We included observational studies representative of general patients aged ≥60 in which PP was defined as multiple drugs ≥5. Studies were excluded if only a particular group of the elderly population (e.g., with diabetes) were included. The primary outcome was the prevalence of PP. Random‐effect models were employed to estimate the overall or variable‐specific pooled estimates of PP. Secondary outcomes were hyperpolypharmacy (HPP, defined as multiple drugs ≥10) and PP prevalence based on different study years, genders, locations, populations, and so forth.
Results
We included 122 original observational studies with an overall population of 57 328 043 individuals in the meta‐analysis. The overall prevalence of PP and HPP in the elderly population worldwide was 39.1% (95% confidence interval [CI], 35.5%–42.7%) and 13.3% (95% CI, 10.4%–16.5%), respectively. The prevalence of PP in Europe, Oceania, North America, Asia, and South America was 45.8% (95% CI, 41.5%–50.2%), 45.5% (95% CI, 26.7%–64.3%), 40.8% (95% CI, 29.8%–51.6%), 29.0% (95% CI, 20.0%–38.0%), and 28.4% (95% CI, 24.0%–32.8%), respectively ( p < 0.01). Multivariate meta‐regressions showed geographical regions of Europe or North America, age ≥70, and residence from nursing homes were independently associated with higher PP prevalence.
Conclusions
Nearly 40% of the elderly population is exposed to PP. The prevalence of PP is significantly higher in elderly individuals aged 70 or older, in developed regions and in nursing homes. It is important to focus on avoiding inappropriate PP in this population to address the growing burden of PP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fo…
- Department of Gastroenterology, Xi'an Medical University, Xi An, Shaanxi, China.
- Department of Radiotherapy, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, Z., Liu, T., Su, Q., Luo, H., Lou, L., Zhao, L., Kang, X., Pan, Y., & Nie, Y. (2024). Prevalence of Polypharmacy in Elderly Population Worldwide: A Systematic Review and Meta‐Analysis. Pharmacoepidemiology and Drug Safety, 33(8). https://doi.org/10.1002/pds.5880
Vancouver
Wang Z, Liu T, Su Q, Luo H, Lou L, Zhao L, et al. Prevalence of Polypharmacy in Elderly Population Worldwide: A Systematic Review and Meta‐Analysis. Pharmacoepidemiology and Drug Safety. 2024;33(8). doi:10.1002/pds.5880
BibTeX
@article{Wang2024,
author = {Wang, Zeyu and Liu, Tangyi and Su, Qiaoyu and Luo, Hui and Lou, Lijun and Zhao, Lina and Kang, Xiaoyu and Pan, Yanglin and Nie, Yongzhan},
title = {Prevalence of Polypharmacy in Elderly Population Worldwide: A Systematic Review and Meta‐Analysis},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
volume = {33},
number = {8},
doi = {10.1002/pds.5880}
}
EUVIMED